Aurobindo Pharma Limited    
16 Aug 2017
698.50
0.44%
Axis Direct
Gross margin improved 50 bps QoQ and EBITDA margin 170 bps QoQ on 8% QoQ growth in US sales and improving revenue mix (higher formulations and lower API/ ARV sales). However, PAT declined 11% YoY/ 3% QoQ on higher depreciation due to commissioning of new units.
Number of FIIs/FPIs holding stock fell by 29 to 769 in Jun 2017 qtr.
Aurobindo Pharma Limited    
14 Aug 2017
698.50
0.44%
buy
Angel Broking
For 1QFY2018 Aurobindo Pharma (APL) posted numbers lower than expectations on sales, OPM and net profit fronts. On sales front, the company posted sales of `3621cr (v/s. `3,900cr expected) v/s. `3,664cr in 1QFY2017, posting a yoy de-growth of 1.2%. On the operating front, the EBITDA margin came in at 21.1% (v/s. 22.9% expected) v/s. 22.6%..
default
Aurobindo Pharma Limited has an average target of 823.73 from 12 brokers.
Aurobindo Pharma Limited    
11 Aug 2017
698.50
0.44%
BP Wealth
declined by 1.3% YoY due to flattish growth in the US, negative contribution from ARV (-19% YoY) and API (-15% YoY) business. EBITDA for the quarter stood at Rs 8.4bn (est. Rs 8.6bn) down 5.3% YoY with EBITDA margins at 22.9% vs 23.9% the same period year ago. PAT for the quarter stood at Rs...
Axis Direct decreased Buy price target of Aurobindo Pharma Limited to 825.0 on 16 Aug, 2017.
Aurobindo Pharma Limited    
11 Aug 2017
698.50
0.44%
Nirmal Bang Institutional
Upgrade To Buy As Valuation Becomes Favorable Aurobindo Pharma or APL's 1QFY18 revenues at Rs36,788mn and net earnings at Rs518mn were below our expectations. Revenues were 5% below our/consensus estimate each while net earnings were 13%/9% below our/consensus estimate, respectively. However, unlike peers, the pain of price erosion was much lower as it was offset by new product launches and margin improvement in EU business. US and European business grew sequentially. Europe business growth and margin expansion was aided by consolidation of Generis Farmaceutica and site transfers of products to Indian manufacturing facilities. Out of the 180 products in Actavis portfolio, 71 products have been...
Promoters pledge reduced to 1.22% of holdings in Jun 2017 qtr.
Aurobindo Pharma Limited    
10 Aug 2017
698.50
0.44%
Business Line
Shares of Aurobindo Pharma surged almost 6 per cent in early trade on Thursday, despite reporting a decline in net profit for the latest June quarter. Better visibility in earnings growth in the...
default
Aurobindo Pharma Limited    
10 Aug 2017
698.50
0.44%
HDFC Securities
Maintain BUY rating with a revised TP of Rs 790 (16x Jun19E). A favourable business mix in 1QFY18 led to Aurobindos (ARBP) EBITDA margin beating estimates by ~130bps. Lower contribution from APIs drove gross margin up ~180bps. The top-line declined ~2% vs our estimates of ~3% growth, largely on account of reduction in the API (owing to the GST disruption) and ARV businesses. The US business was flat YoY, and the European biz (+10% YoY) was boosted by sales from the Generis acquisition. PAT at Rs 5.1bn was down 17%YoY, in-line with estimates.
Promoters pledge reduced to 1.22% of holdings in Jun 2017 qtr.
Aurobindo Pharma Limited    
10 Aug 2017
698.50
0.44%
Aurobindo Pharma says pricing pressure is bottoming out in earnings call, as Jhunjhunwala questions management click to expand

Aurobindo Pharma management, in its earnings call with investors and analysts today morning, said an item of note: it acknowledged that price erosion was in the double-digit % YoY, rather than single digits which it had expected. Quarterly price erosion however was flat, suggesting that the fall in price has been arrested going forward.

The management received questions from investor Rakesh Jhunjhunwala, who owns over 1.12% of the company.  Jhunjhunwala had praised the company's performance "in difficult circumstances", with the FDA pushing for greater competition in the US generics market to bring prices down. AuroPharma management, responding to his questions on pricing, said that they don't expect drug prices to see a downside of more than 5% in the coming quarters.

The company's Europe business has grown strongly,  crossing into double digits in EBITDA margins. This however didn't arrest the slide in the firm's overall numbers - US generics sales have been flat, and revenues from API formulations are also down. Aurobindo is however, moving aggressively on complex formulations, such as the gRenvela tablet it recently launched and received approval for. The company did not include Renvala sales in Q1 earnings. 

Aurobindo Pharma Limited    
10 Aug 2017
698.50
0.44%
Motilal Oswal
Ahead of peers; 2Q expected to be best-ever quarter Net sales declined ~2% YoY (+~1% QoQ) to ~INR36.8b (est. of ~INR40.7b). US business grew 3.2% YoY (+7% QoQ) to USD263m. In INR terms, US sales remained largely flat YoY due to currency movement. Gross margin improved to 59% (+400bp YoY, flat QoQ). EBITDA declined 5% YoY to ~INR8.4b (est. of INR9.2b), with the margin at 22.9% (-70bp YoY, +~170bp QoQ). Adj. PAT declined 9.7% YoY (-6% QoQ) to INR5.2b, ~13% below our estimate....
default
Aurobindo Pharma Limited is trading above it's 200 day SMA of 676.07
Aurobindo Pharma Limited    
10 Aug 2017
698.50
0.44%
Reliance Securities
Injectable Portfolio, New Launches to Drive US Biz; Maintain BUY Aurobindo Pharma (ARBP) has delivered a better performance compared to its peers in 1QFY18. Its sales, EBITDA and net profit stood at Rs36.8bn, Rs8.4bn and Rs5.3bn, respectively. Despite challenging environment, its US revenue increased by 3.5% YoY and 7.0% QoQ (in CC term), which albeit declined by 0.5% YoY in INR terms due to adverse currency. Led by weak performance in ARV (down 19.3% YoY) and API business (down 14.9% YoY), ARBP's revenue declined 2.3% YoY. Gross margin rose by 274bps YoY and 59bps QoQ to 59.3% owing to better product mix. Despite 11% QoQ rise in R&D; spend, EBITDA margin rose by 170bps QoQ due to...
Aurobindo Pharma Limited is trading below it's 30 day SMA of 723.28
Aurobindo Pharma Limited    
10 Aug 2017
698.50
0.44%
ICICI Securities Limited
Revenues remained flat YoY at | 3679 crore (I-direct estimate: | 3671 crore) driven by 10% growth in the Europe to | 918 crore (I-direct estimate: | 839 crore). US growth was flat at | 1695 crore (I-direct estimate: | 1661 crore) despite strong headwinds. ARV business declined 19% to | 245 crore (I-direct estimate: | 318 crore) whereas APIs declined 15% to | 625 crore EBITDA margins declined 72 bps YoY to 22.9% (I-direct estimate: 20.9%) due to higher employee and other expenditure...
Promoters pledge reduced to 1.22% of holdings in Jun 2017 qtr.
  • Axis Direct decreased Buy price target of Aurobindo Pharma Limited to 825.0 on 16 Aug, 2017.
  • Stock Price (704.80) crossed above 50 Day SMA (685.95) on 11 August, 2017
  • Stock Price (684.15) crossed below 30 Day SMA (719.01) on 09 August, 2017
  • Month Change by 22.81% (Crossed threshold 20%) on 22 June, 2017
  • Stock Price (652.65) crossed above 100 Day SMA (644.09) on 16 June, 2017
More triggered alerts
Ex-Date Dividend Amount Dividend Type Record Date
June 8, 20171.25INTERIM-
Nov. 24, 20161.25INTERIM-
June 9, 20160.70INTERIM-
Feb. 18, 20160.70INTERIM-
Nov. 19, 20150.60INTERIM-
All dividends by AUROPHARMA
Ex-Date Dividend Bonus Ratio Record Date
July 20, 20151:1July 21, 2015
All bonuses by AUROPHARMA
Ex-Date Dividend Old FVNew FV Record Date
Feb. 10, 201151Feb. 11, 2011
All splits by AUROPHARMA